Loss of UHRF2 Is Associated With Non-small Cell Lung Carcinoma Progression

被引:16
|
作者
Jin, Chun [1 ]
Xiong, Dian [2 ]
Li, Hao-Ran [1 ]
Jiang, Jia-Hao [1 ]
Qi, Jian-Chao [3 ]
Ding, Jian-Yong [1 ]
机构
[1] Fudan Univ, Affiliated Zhongshan Hosp, Dept Thorac Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[2] Nanchang Univ, Affiliated Hosp 2, Dept Cardiothorac Surg, Nanchang 330000, Jiangxi, Peoples R China
[3] Fujian Prov Hosp, Dept Emergency Surg, Fuzhou 350001, Fujian, Peoples R China
来源
JOURNAL OF CANCER | 2018年 / 9卷 / 17期
关键词
NSCLC; UHRF2; 5-hmC; demethylation; CYCLE NETWORK; TET ENZYMES; 5-HYDROXYMETHYLCYTOSINE; GENOME; TDG; HYPERMETHYLATION; 5-METHYLCYTOSINE; EXPRESSION; TARGET;
D O I
10.7150/jca.25876
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent evidence indicated ubiquitin like with PHD and ring finger domains 2 (UHRF2) was involved in various human diseases, especially in cancer, however, its roles in cancer are still in dispute. Here, we found UHRF2 expression was decreased in lung cancer tissues compared with adjacent normal tissues by referring to the Oncomine Database, which was further identified by immunoblotting and quantitative real-time polymerase chain reaction assays. Secondly, we found knockdown of UHRF2 in A549 and 95-D cell lines enhanced the capability of proliferation, invasion and migration, while forced UHRF2 expression inhibited NSCLC cells proliferation,invasion and migration. Mechanistically, dot-blot and western blot assays indicated that the level of UHRF2 was positively correlated with 5-hmC level by affecting ten-eleven translocation 2 (TET2) expression. Clinically, UHRF2 downregulation is significantly correlated with a malignant phenotype, including larger tumor size and poor differentiation. Moreover, UHRF2 downregulated correlates with shorter overall survival(OS). Conclusion: Our findings indicate that UHRF2 is a tumor suppressor in NSCLC by influence TET2 expression and serve as a potential therapeutic target in NSCLC.
引用
收藏
页码:2994 / 3005
页数:12
相关论文
共 50 条
  • [31] Genes and Pathology of Non-Small Cell Lung Carcinoma
    Sakashita, Shingo
    Sakashita, Mai
    Tsao, Ming Sound
    SEMINARS IN ONCOLOGY, 2014, 41 (01) : 28 - 39
  • [32] Prognostic factors in non-small cell lung carcinoma
    Koutsami, MK
    Gorgoulis, VG
    Kastrinakis, NG
    Asimacopoulos, PJ
    Kittas, C
    ANTICANCER RESEARCH, 2002, 22 (1A) : 347 - 374
  • [33] Sleeve segmentectomy for non-small cell lung carcinoma
    Okada, M
    Nishio, W
    Sakamoto, T
    Uchino, K
    Yuki, T
    Nakagawa, A
    Tsubota, N
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 128 (03): : 420 - 424
  • [34] Molecular Diagnostics in Non-Small Cell Lung Carcinoma
    Sholl, Lynette M.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 386 - 399
  • [35] KRAS Amplification in Non-Small Cell Lung Carcinoma
    Stiedl, A. C.
    Wagner, P. L.
    Wilbertz, T.
    Altorki, N. K.
    Perner, S. R.
    MODERN PATHOLOGY, 2010, 23 : 414A - 414A
  • [36] NON-SMALL CELL-CARCINOMA OF THE LUNG - INTRODUCTION
    GOLOMB, HM
    SEMINARS IN ONCOLOGY, 1983, 10 (01) : 1 - 2
  • [37] Low LATS2 EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN NON-SMALL CELL LUNG CARCINOMA
    Jang, Si-Hyong
    Oh, Mee-Hye
    Cho, Hyun Deuk
    Lee, Ji-Hye
    Lee, Hyun Ju
    Ahn, Hyein
    Kim, Han Jo
    POLISH JOURNAL OF PATHOLOGY, 2019, 70 (03) : 189 - 197
  • [38] Identification of RHEX as a novel biomarker related to progression and immunity of non-small cell lung carcinoma
    Xu, Tao
    Dai, Tianyang
    Zeng, Peiyuan
    Song, Qi
    He, Kaiming
    Hu, Zhi
    Li, Yuan
    Li, Zhou
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (08) : 3811 - +
  • [39] Advanced glycation end-products impair the non-small cell lung carcinoma progression
    Bartling, B.
    Hofmann, H. -S.
    Sohst, A.
    Silber, R. -E.
    Somoza, V.
    Simm, A.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2014, 47 : 16 - 16
  • [40] Gene Fusions Detected in Non-Small Cell Lung Carcinoma (NSCLC) and Small Cell Lung Carcinoma (SCLC)
    Arguello, David
    Swensen, Jeff
    Ellis, Phil
    Kimbrough, Jeff
    Voss, Andreas
    Gatalica, Zoran
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S221 - S221